J Korean Rheum Assoc.  2009 Sep;16(3):197-203.

Bucillamine-induced Nephropathy

• Kim HA
• Yim HE
• Sung JM
• Lee JW
• Suh CH

Abstract

OBJECTIVE
Bucillamine is a disease-modifying antirheumatic drug that's widely used in Korea and Japan, and it is reported to be a cause of proteinuria. However, the clinical course of the nephropathy associated with the use of bucillamine in rheumatoid arthritis patients has not been described in detail in Korea. METHODS: We examined clinical records of 835 patients who were treated with bucillamine for rheumatoid arthritis at least 2 months at Ajou University Hospital from 2003 to 2008, and we found 23 patients (2.75%) with proteinuria. Each patient was followed up until the proteinuria had resolved. RESULTS: At the time the proteinuria developed, the mean age of patients was 53.8+/-11.0 years. Only one patient had marked hypoalbuminemia (<3.0 g/dL). The mean value of the random urine protein-creatinine ratio was 3.44+/-2.99. The proteinuria appeared 4~18 months after the initiation of the treatment with bucillamine. Among the patients, renal biopsy was carried out in 18 patients, and pathological findings were 17 cases of membranous glomerulopathy and 1 case of focal segmental glomerulosclerosis. On the follow-up of the 18 patients, the proteinuria in all the patients had resolved completely without deterioration of renal function. But the time to resolution of the proteinuria was positively correlated with the length of bucillamine treatment after the onset of proteinuria (p<0.001, r=0.744). CONCLUSION: Prevalence of proteinuria in patients receiving bucillamine was 2.75%, and bucillamine-induced nephropathy showed a good prognosis in Korea. The most important thing for resolving the bucillamine-induced proteinuria is to discontinue the bucillamine.

Keyword

Rheumatoid arthritis; Bucillamine; Nephropathy

MeSH Terms

Arthritis, Rheumatoid
Biopsy
Cysteine
Follow-Up Studies
Glomerulonephritis, Membranous
Glomerulosclerosis, Focal Segmental
Humans
Hypoalbuminemia
Japan
Korea
Prevalence
Prognosis
Proteinuria
Cysteine
Glomerulosclerosis, Focal Segmental

Figure

• 

  Fig. 1. Correlation between interval to remission of proteinuria and bucillamine exposure time after onset of proteinuria.

Reference

References

1. Boers M. Renal disorders in rheumatoid arthritis. Semin Arthritis Rheum. 1990; 20:57–68.

2. Dische FE, Swinson DR, Hamilton EB, Parsons V. Immunopathology of penicillamine-induced glomerular disease. J Rheumatol. 1984; 11:584–5.

3. Golding JR, Andrews FM, Camp V, Day AT, Freeman AM, Golding DN, et al. Controlled trial of penicillamine in severe rheumatoid arthritis. Ann Rheum Dis. 1973; 32:385–6.

4. Tubbs RR, Valenzuela R, McCormack LJ, Pohl MA. Gold nephropathy. N Engl J Med. 1977; 296:1413–4.

5. Hall CL, Fothergill NJ, Blackwell MM, Harrison PR, MacKenzie JC, MacIver AG. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed). 1987; 295:745–8.

6. Hall CL, Jawad S, Harrison PR, MacKenzie JC, Bacon PA, Klouda PT, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed). 1988; 296:1083–6.

7. Goto M, Sasano M, Nishioka K. Decrease in disease activity and concomitant increase in the percentage of peripheral blood suppressor T-cells in rheumatoid arthritis by a newly synthesized slow-acting antirheumatic drug (Bucillamine). Int J Immunopharmacol. 1989; 11:327–31.

8. Nagahama K, Matsushita H, Hara M, Ubara Y, Hara S, Yamada A. Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis. 2002; 39:706–12.

9. Obayashi M, Uzu T, Harada T, Yamato M, Takahara K, Yamauchi A. Clinical course of bucillamineinduced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol. 2003; 7:275–8.

10. Hoshino J, Ubara Y, Hara S, Suwabe T, Sawa N, Tagami T, et al. Outcome and treatment of bucillamine-induced nephropathy. Nephron Clin Pract. 2006; 104:15–9.

11. Bae SC, Lee IH, Yoo DH, Kim SY. Clinical trial of N-(2-Mercapto-2-methylpropionyl)-L-cystein (SA96) in patients with rheumatoid arthritis. Korean J Med. 1993; 44:416–24.

12. Song CH, Lee JS, Lee CH, Lee CW, Suh CH, Song JS, et al. The effect of bucillamine in the inital treatment of rheumatoid arthritis and treatment of patients with refractory rheumatoid arthritis. J Korean Rheum Assoc. 1998; 5:83–8.

13. Helin H, Korpela M, Mustonen J, Pasternack A. Mild mesangial glomerulopathy–a frequent finding in rheumatoid arthritis patients with hematuria or proteinuria. Nephron. 1986; 42:224–30.

14. Helin HJ, Korpela MM, Mustonen JT, Pasternack AI. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995; 38:242–7.

15. Salomon MI, Gallo G, Poon TP, Goldblat MV, Tchertkoff V. The kidney in rheumatoid arthritis. A study based on renal biopsies. Nephron. 1974; 12:297–310.

16. Koseki Y, Terai C, Moriguchi M, Uesato M, Kamatani N. A prospective study of renal disease in patients with early rheumatoid arthritis. Ann Rheum Dis. 2001; 60:327–31.

17. Nakano M, Ueno M, Nishi S, Shimada H, Hasegawa H, Watanabe T, et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis. Clin Nephrol. 1998; 50:154–60.